Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application for fluzoparib, a PARP inhibitor, in combination with abiraterone and prednisone (or prednisolone) for the treatment of adult patients with metastatic castration‑resistant prostate cancer (mCRPC) – marking the first regulatory filing outside China for the company’s first‑in‑class domestically developed PARP inhibitor.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | EMA (European Union) |
| Application Type | Marketing Authorization Application (MAA) |
| Product | Fluzoparib (PARP inhibitor) |
| Combination Regimen | Fluzoparib + abiraterone acetate + prednisone/prednisolone |
| Indication | First‑line treatment of adults with metastatic castration‑resistant prostate cancer (mCRPC) |
| Acceptance Date | 9 Oct 2026 |
| Prior Approval | China NMPA (Dec 2020, first independently developed PARP inhibitor approved in China) |
| Pivotal Trial | FUZUPRO (SHR3162‑III‑305), international multicenter Phase III |
Drug Profile & Mechanism of Action
- Molecule: Fluzoparib – a highly selective, orally bioavailable poly (ADP‑ribose) polymerase (PARP) inhibitor
- Target: PARP‑1 and PARP‑2 enzymes critical for DNA single‑strand break repair; inhibition induces synthetic lethality in tumor cells with defective homologous recombination repair (HRR) pathways
- Innovation: The first PARP inhibitor independently developed and approved in China (Dec 2020), demonstrating Hengrui’s capability in bringing novel oncology assets from discovery through international regulatory filings
- Combination Rationale: PARP inhibition combined with abiraterone (CYP17A1 inhibitor that blocks androgen biosynthesis) targets mCRPC through dual mechanisms – DNA damage repair disruption and androgen signaling suppression – a synergistic approach supported by emerging clinical evidence in the PARP inhibitor class
- Global Development: EMA filing represents Hengrui’s strategic push into European oncology markets, building on domestic commercialization experience since 2020
Clinical Evidence – Phase III FUZUPRO Study
| Endpoint | Result | Comparator |
|---|---|---|
| Radiographic Progression‑Free Survival (rPFS) | 24.8 months (fluzoparib + AA‑P) | 19.9 months (placebo + AA‑P) |
| rPFS Improvement | +4.9 months median, statistically significant | – |
| Safety Profile | Tolerable, consistent with PARP inhibitor class | – |
| Trial Design | International, multicenter, randomized, double‑blind, placebo‑controlled Phase III | – |
| Population | Patients with mCRPC, first‑line setting | – |
| Regimen | Fluzoparib + abiraterone acetate + prednisone (AA‑P) | Placebo + AA‑P |
The FUZUPRO study (SHR3162‑III‑305) was designed as a global registration‑enabling trial with sites across multiple countries. The 4.9‑month median rPFS improvement over the current standard of care (abiraterone + prednisone alone) positions fluzoparib as a potentially meaningful addition to the mCRPC treatment arsenal, particularly in a disease setting where incremental survival gains carry substantial clinical and economic value.
Market Impact & Outlook
- mCRPC Landscape: Metastatic castration‑resistant prostate cancer remains a high‑mortality disease with a median survival of approximately 2–3 years. The addition of a PARP inhibitor to androgen‑axis therapy represents an emerging treatment paradigm, with regulatory precedents already established in the EU for other PARP inhibitors in biomarker‑selected prostate cancer populations.
- European Market Entry: EMA acceptance of the MAA signals Hengrui’s ambition to commercialize beyond China, entering one of the world’s most lucrative oncology markets. A positive EMA opinion could open the door to approvals across all 27 EU member states plus associated countries.
- Competitive Differentiation: The FUZUPRO data demonstrated benefit in a broad mCRPC population (not restricted to HRR‑mutated patients), potentially offering a wider label than some competing PARP inhibitors that require biomarker selection.
- Class Validation: The PARP inhibitor + abiraterone combination approach has been validated by multiple Phase III programs, lending credibility to fluzoparib’s mechanism and supporting the likelihood of regulatory success in the EU.
- Hengrui’s Global Strategy: This filing is a milestone in Hengrui’s transformation from a China‑centric pharma into a global oncology player, leveraging its deep pipeline and clinical development capabilities to pursue international revenue streams.
- Regulatory Timeline: EMA review typically spans 12–15 months from acceptance to Committee for Medicinal Products for Human Use (CHMP) opinion; a PDUFA‑equivalent timeline has not been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review, clinical efficacy, and commercial potential of fluzoparib in the European Union. EMA acceptance of a marketing application does not guarantee approval. Actual outcomes may differ due to risks including regulatory decisions, post‑marketing commitments, competitive dynamics, pricing and reimbursement negotiations, and the inherent uncertainties of international drug commercialization.-Fineline Info & Tech
